吡咯萘啶-青蒿琥酯治疗无症状疟疾感染者的疗效、安全性与耐受性:一项随机对照试验
该II期多中心开放标签随机对照试验在冈比亚和赞比亚纳入303例镜检确诊的无症状恶性疟原虫感染者,按1:1:1随机接受吡咯萘啶-青蒿琥酯3天、2天或1天方案。第28天PCR校正的充分寄生虫学应答率3天和2天方案均为100%,1天方案为96.8%;3天和2天方案疗效维持至第63天,1天方案降至94.4%。不良事件频率各组相似,多数为1-2级,结论支持进一步研究该药用于群体给药。
要点
- 3天和2天方案的第28天PCR校正APR均为100%,1天方案为96.8%。
- 3天和2天方案疗效维持至第63天达100%,1天方案降至94.4%。
- 不良事件多为1-2级,无症状性转氨酶短暂升高见于2.0%参与者。
核心结论
- 吡咯萘啶-青蒿琥酯在无症状恶性疟原虫感染者中具有高疗效和良好耐受性,3天与2天方案疗效相似,支持进一步研究其用于群体给药。
研究设计与样本
- II期、多中心、开放标签、随机对照试验,在冈比亚和赞比亚开展,共随机303例镜检确诊的无症状恶性疟原虫感染者,按1:1:1分配至3天、2天或1天吡咯萘啶-青蒿琥酯(180:60 mg)方案,按体重给药。
主要发现
- 第28天PCR校正的充分寄生虫学应答率:3天方案100%(98/98),2天方案100%(96/96),1天方案96.8%(89/94)。
- 第63天疗效:3天和2天方案维持100%,1天方案降至94.4%(84/89)。
- 不良事件频率:3天方案51.5%(52/101),2天方案52.5%(52/99),1天方案54.4%(56/103);多数为1级或2级(85%[136/160])。
- 无症状、短暂性丙氨酸氨基转移酶/天冬氨酸氨基转移酶升高(>3倍正常上限)见于6/301(2.0%)参与者。
临床怎么用
- 在无症状恶性疟原虫感染者中,3天和2天吡咯萘啶-青蒿琥酯方案均显示高 efficacy,但应鼓励对3天方案的良好依从性。
- 1天方案疗效较低且至第63天下降,不作为首选。
- 治疗期间需关注转氨酶短暂升高,但多数不良事件为轻中度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pyronaridine-artesunate (PA) is a registered artemisinin-based combination therapy, potentially useful for mass drug administration campaigns. However, further data are needed to evaluate its efficacy, safety and tolerability as full or incomplete treatment in asymptomatic Plasmodium falciparum-infected individuals. METHODS: This phase II, multi-center, open label, randomized clinical trial was conducted in The Gambia and Zambia. Participants with microscopically confirmed asymptomatic P. falciparum infection were randomly assigned (1:1:1) to receive a 3-day, 2-day, or 1-day treatment regimen of PA (180:60 mg), dosed according to bodyweight. The primary efficacy outcome was polymerase chain reaction (PCR)-adjusted adequate parasitological response (APR) at day 28 in the per-protocol population. RESULTS: A total of 303 participants were randomized. Day 28 PCR-adjusted APR was 100% for both the 3-day (98/98) and 2-day regimens (96/96), and 96.8% (89/94) for the 1-day regimen. Efficacy was maintained at 100% until day 63 for the 3-day and 2-day regimens but declined to 94.4% (84/89) with the 1-day regimen. Adverse event frequency was similar between the 3-day (51.5% [52/101]), 2-day (52.5% [52/99]), and 1-day (54.4% [56/103]) regimens; the majority of adverse events were of grade 1 or 2 severity (85% [136/160]). Asymptomatic, transient increases (>3 times the upper limit of normal) in alanine aminotransferase/aspartate aminotransferase were observed for 6/301 (2.0%) participants. CONCLUSIONS: PA had high efficacy and good tolerability in asymptomatic P. falciparum-infected individuals, with similar efficacy for the full 3-day and incomplete 2-day regimens. Although good adherence to the 3-day regimen should be encouraged, these results support the further investigation of PA for mass drug administration campaigns. CLINICAL TRIALS REGISTRATION: NCT03814616.
引用
- Dabira ED, Hachizovu S, Conteh B, et al. Efficacy, Safety and Tolerability of Pyronaridine-artesunate in Asymptomatic Malaria-infected Individuals: a Randomized Controlled Trial. Clin Infect Dis. 2022. PMID: 33983371. doi:10.1093/cid/ciab425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。